BACKGROUND: Data on radiotherapy for trigeminal schwannomas (TSs) and comparison of stereotactic radiosurgery (SRS) with fractionated stereotactic radiotherapy (FSRT) are limited. OBJECTIVE: We present a large retrospective review of our institutional experience treating TSs with SRS and FSRT. We also describe a flare phenomenon experienced by some patients. METHODS: The records of 23 consecutive TSs patients treated with radiotherapy between 1996 and 2011 were reviewed. We investigated radiographic response, tumor control, and toxicity. RESULTS: Ten patients underwent SRS and 13 underwent FSRT, with median clinical follow-up of 32 months (range, 3-120 months). Tumor control at 5 and 10 years was 94% overall. Symptom control at 5 years was achieved in 48% of all patients, with nonsignificant improvement in more patients in the FSRT group than those in the SRS group (56% vs 40%, P = .37). Acute toxicity was higher in the FSRT group (38.5 vs 0%, P , .01), although lesions treated with FSRT were larger (mean, 9.5 mL vs 4.8 mL, P , .01). A symptomatic flare phenomenon occurred in 2 patients (8.7% overall) during FSRT, involving transient cystic formation and dramatic size increase. One lesion regressed in size and 1 remained stable on follow-up. CONCLUSION: Tumor control rates for TSs are excellent with SRS and FSRT with minimal toxicity. This represents the first documented report of a flare phenomenon after FSRT for TS treatment. Flare risk after FSRT in previously resected large lesions should be discussed with patients before treatment, and prophylactic oral steroids may be considered. They are the second most common schwannoma affecting the cranial nerves, representing 1% to 8% of intracranial schwannomas.
T rigeminal schwannomas (TSs) are rare, benign, slow-growing lesions, occurring most frequently in middle-aged patients. 1 They are the second most common schwannoma affecting the cranial nerves, representing 1% to 8% of intracranial schwannomas. 2 Patients frequently present with trigeminal nerve and surrounding cranial nerve dysfunction manifested as pain, numbness, and masticator muscle weakness, although some patients may remain asymptomatic. 3 TSs had been traditionally treated with microsurgical resection, with reported control rates of 83% to 100%. 4, 5 Stereotactic radiation in the form of stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) has more recently become a standard treatment option. Initial literature in patients treated with stereotactic radiotherapy for acoustic schwannomas reported favorable outcomes with decreased treatment toxicity and cranial neuropathy compared with surgical resection. 6, 7 Several studies on TSs have reported on tumor control with both SRS and FSRT, revealing control rates of 88% to 100%, comparable to rates of surgical treatment.
Although SRS and FSRT are both effective for tumor control of TSs, there is a theoretical benefit with FSRT of an increased therapeutic ratio because of the smaller fraction size per treatment, resulting in reduced normal tissue toxicity and higher rates of cranial nerve function. 13 This has been shown in radiobiological modeling, but it remains to be proven clinically. Our institution has traditionally favored the use of FSRT in patients with larger tumors and functioning cranial nerves in an effort to reduce the risk of both acute and late treatment toxicity to normal tissue structures while optimizing cranial nerve function preservation. This has previously been reported for our experience with acoustic schwannomas, and we extrapolate the results to all cranial nerve schwannomas.
14 Since these findings, we generally recommend FSRT for all patients because of its theoretical toxicity benefits. We also offer SRS treatment to all patients because of its convenience, but reserve recommendation for patients with smaller lesions and limited residual cranial nerve function.
This study serves to report on our experience treating TSs with both SRS and FSRT, comparing outcomes and toxicity of each treatment modality.
PATIENTS AND METHODS
After obtaining institutional review board approval, we identified 23 consecutive patients with TSs diagnosed by magnetic resonance imaging (MRI) or surgical resection who received stereotactic radiotherapy at the Jefferson Hospital for Neuroscience, Thomas Jefferson University, between 1996 and 2011. Medical records for these patients were reviewed, including in-patient hospital notes, MRI scans, radiotherapy treatment records, and radiation therapy and neurosurgery outpatient follow-up encounters.
Radiotherapy Treatment
Our institutional policy dictates that all patients are thoroughly evaluated and discussed by a multidisciplinary tumor board, consisting of neurosurgeons (J.J.E., D.W.A.), radiation oncologists (W.S., M.W.), and neuroradiologists. Treatment decisions for SRS or FSRT are based on a thorough discussion evaluating tumor size, symptoms, cranial nerve function, performance status, and patient preference. Patients are generally offered FSRT with emphasis placed on those with intact cranial nerve function. However, patient preference for SRS because of the convenience of a single treatment may override this recommendation.
Patients treated before June 2004 with FSRT received radiotherapy via a Varian Clinac-600SR linear accelerator (LINAC, Varian 600SR; Varian Corp, Palo Alto, California) and were immobilized with Brown-RobertsWells and Gill-Thomas-Cosman relocatable frames (Radionics Inc., Burlington, MA), using the Radionics (RSA, Radionics Inc., Burlington, MA) planning system. Patients treated after 2004 with FSRT received radiotherapy via a Brainlab Novalis 600 LINAC (Varian Corp) using the Exac Trac feature for localization and the Brainlab mask for immobilization ( Figure 1 ).
Patients treated with SRS before May 2006 received treatment with Gamma Knife (Model U; Elekta Instruments, Atlanta, Georgia) and after with Gamma Knife model 4C, both with standard delivery techniques for SRS. Several patients also received treatment with the LINACs described previously. Treatment planning was performed with the Leksell GammaPlan (Elekta Instruments) and Brainlab (Novalis) software ( Figure 2 ). All patients treated with SRS are given a prophylactic steroid on the day of treatment intravenously.
Enhancement on T1-weighted, contrast-enhanced MRI was contoured and included as gross tumor volume (GTV). No margin was added to the GTV in either treatment modality.
Toxicity Evaluation and Follow-up
Patients were initially seen in follow-up 3 to 6 months after treatment by the radiation oncology and neurosurgery teams, although patients experiencing acute toxicity were seen earlier. Patients were then followed with yearly MRI for a scheduled period of 10 years. At this point, if there was no sign of progression or treatment failure, patients were followed on an as-needed basis only. Follow-up was measured from the beginning of radiotherapy until the last documented encounter by either team. Tumor control was defined as stable or decreased tumor size on follow-up MRI compared with pretreatment imaging, including radiographic response and tumor necrosis.
Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) (National Cancer Institute, Bethesda, Maryland) was used to quantify all toxicity measurements. Acute toxicity was defined as an event within 3 months of SRS or within 3 months from the beginning of FSRT. Long-term toxicity was defined as events beyond 3 months in both groups.
Statistical Analysis
Statistical analyses were performed using the STATA Statistical Package version IC 11.1 (StataCorp, Inc, College Station, Texas). Student's paired t test was performed to individually compare treatment modality, size, and outcomes. Acute toxicity was analyzed and calculated for the entire population and the SRS and FSRT subgroups individually. Chronic toxicity, cranial nerve function, and symptomatic control rates between SRS and FSRT were estimated using the Kaplan-Meier method using GraphPad Prism version 5 (GraphPad Software, San Diego, California), and curves were compared using the log-rank test. Logistic regression was performed to evaluate treatment type and tumor variables predicting for acute and chronic toxicity between SRS and FSRT. Variables included in the analysis were age, Karnofsky Performance Status (KPS), tumor volume, treatment type (SRS or FSRT), and surgical resection. A P value ,.05 was considered statistically significant.
RESULTS
Median clinical follow-up time was 32 months (range, 3-120 months), with 1 patient in the FSRT group lost to followup. All patients had imaging studies performed within 1 month of their final follow-up visit. Two patients completed 10-year followup with imaging showing stable size at last visit and long-term treatment success. These patients were told to continue followup as needed. Six patients failed to return for follow-up after a radiographic response was seen at 15 months (range, 3-29 months). All 6 were asymptomatic at last follow-up. Overall, the median KPS was 90 and mean age was 45 years, with no statistically significant difference between SRS and FSRT treatment groups.
Pathological diagnosis was confirmed in 10 patients (3/10 [30%] in the SRS group and 7/13 [54%] in the FSRT group; P = .16). Pathology revealed grade I schwannomas of the trigeminal nerve in all 10 patients.
Ten patients received SRS to a median dose of 13.75 Gy (range, 12-15 Gy) and 13 received FSRT to a median dose of 50.4 Gy (range, 49.8-50.4 Gy) in 1.8-Gy fractions, with 1 patient (49.8 Gy) receiving altered fractionation because of the inability to complete treatment. Nine patients received radiotherapy for residual tumor at a median of 3 months (range, 1-6 months) after surgery, and 1 patient was treated after his lesion recurred 131 months after resection. Median tumor size was 4.8 mL (range, 0.4-13.8 mL; mean, 7.5 mL) for the SRS group and 9.5 mL (range, 0.5-28.5 mL; P , .01) for the FSRT group. The overall median tumor size was 5.03 mL (range, 0.35-28.52 mL). Table 1 provides patient characteristics.
Tumor Control
Tumor control at 5 and 10 years was achieved in 94% of all patients. Local control at 5 years was not significantly different between the 2 treatment groups (100% FSRT group vs 87.5% SRS group, P = .31). Figure 3 illustrates the Kaplan-Meier curves for tumor control. Six patients had a reduction in size of their lesion on MRI (SRS = 2, FSRT = 4) at a mean time of 15 months (range, 3-29 months), although these results are hindered by limited long-term follow-up. All 6 patients preferred to follow up on an as-needed basis and if symptomatic, and all failed to follow up. Table 2 lists the treatment outcomes.
Symptomatic Outcome
Twenty-two patients had adequate follow-up for analysis of nerve function and acute and late symptoms, with 1 patient lost to followup after treatment. Symptomatic control at 5 years was achieved in 48% of all patients. Two patients (9.1%) had worsening of pain at 1-year follow up (1 in each treatment group). Of those patients with worsening of symptoms, the patient in the SRS group had symptomatic resolution at 24 months, whereas the FSRT patient had continued facial pain not requiring intervention at last followup (25 months). Symptom control was improved in more patients in the FSRT than those in the SRS group at 5 years (56% vs 40%, P = .37), although this was not statistically significant ( Figure 4) . However, patients undergoing FSRT had greater nerve function before treatment, presenting more often with only symptoms of pain (FSRT: 53.9%, n = 7; SRS: 30%, n = 3).
Toxicity
Acute toxicity requiring oral steroid or pain medication intervention or grade 2 CTCAE and higher was greater in the FSRT (n = 5) compared with the SRS group (n = 0, 30.8% vs 0%; P , .01), although lesions treated with FSRT were larger, as stated previously. All 5 patients received medication intervention; 2 patients had CTCAE grade 3 toxicity and 3 had CTCAE grade 2 toxicity. Size was found to be correlated with higher overall acute toxicity (P , .01) on univariate analysis. Only minor acute symptoms requiring no medical intervention were experienced by patients undergoing SRS (n = 2). Comparison of treatment modality with SRS or FSRT, acute symptoms, KPS, and size was performed using logistic regression, with results showing a significant increase in acute toxicity with FSRT, regardless of size (P = .04). However, caution must be taken with this result because of the small sample size.
Although no patients experienced long-term toxicity, a symptomatic flare phenomenon was encountered in 2 patients (8.7% overall, 15% of FSRT group) treated with FSRT on days 7 and 48 of treatment, defined as a transient increase in symptoms and size of the lesions with radiotherapy. MRI confirmed cystic formation and a dramatic increase in size from 6.8 mL to 9.5 mL and 28.5 mL to 34.6 mL at 1 and 2 months after completion of RT, respectively, causing brainstem compression and severe symptoms ( Figure 5 ). Both had undergone surgical resection before treatment. A total of only 3 patients had cystic lesions on pretreatment MRI, all in the FSRT group. Both patients experiencing the flare had cystic components of their lesions. Only 4 lesions in total were larger than 3 cm, and 2 of these patients experienced the flare phenomenon. The 28.5-mL lesion flare resulted in aphasia and ataxia, and the 6.8-mL lesion caused severe facial pain, headache, and numbness. Neither patient required surgical decompression, although both required hospital admission with steroid and narcotic medication administration. Symptoms resolved by 1 month in both. The 34.66-mL lesion was stable at 10 months and remained unchanged after further follow-up. The 6.8-mL lesion actually significantly reduced in size at 44 months and has been stable at this reduced size after further follow-up. Symptomatic resolution occurred in both patients, and both were asymptomatic in the long term. Both lesions were generally larger, and the risk of flare based on size trended toward significance (P = .08).
DISCUSSION
Treatment of TSs with either SRS or FSRT is highly effective for tumor control. Similar findings have been reported in the literature, and our institutional experience echoes these results, as we have previously reported on our experience with both acoustic and nonacoustic schwannomas treated with SRS and FSRT, both resulting in high rates of tumor control. 14, 15 Treatment is generally well tolerated with no long-term toxicity, although several patients experienced acute symptoms. Although acute toxicity was significantly more frequent in the FSRT group (31% vs 0%, P , .01), FSRT resulted in greater long-term symptomatic improvement at 5 years compared with the SRS group (56% vs 40%), although this was not statistically significant. However, patients with greater cranial function before to treatment generally received FSRT, potentially biasing this result.
Conversely, a flare phenomenon was encountered in 2 of 3 patients with cystic TSs undergoing FSRT. Both patients had previous surgical intervention, and both lesions were large (6.8 and 28.5 mL) compared with the overall median tumor size of 5.03 mL.
The group at the University of Pittsburgh reported on their experience with the treatment of TSs with SRS. 16 They described a 33% rate of neurological improvement, with symptoms unchanged in 57.6%, results nearly identical to those of our SRS group. Disease control was excellent with local control rates greater than 90%. There is no mention of a similar flare phenomenon; however, it is important to note that their mean target volume was 4.2 mL (range, 0.5-18.0 mL), which is significantly smaller than our mean volume of 9.5 mL for the FSRT group. However, several lesions in their data were larger than the 6.8-mL lesion that underwent the flare phenomenon in our data set.
A group from Japan commented on FSRT in 5 TS patients treated at their institution. 17 Although their patient numbers were small, they did report on tumor enlargement and cystic changes at 12 months after FSRT in a patient who received 44 Gy in 2-Gy fractions, followed by an additional 10 Gy boost in 2.5-Gy fractions. There is no mention of lesion size, although it was originally resected and recurred. The lesion was enlarged for 32 months and required repeat resection. Similar findings were seen in a comparison of cystic and solid-type vestibular schwannomas treated with fractionated radiotherapy, where the authors described an episode of 2-mm enlargement occurring more frequently in cystic lesions. 18 Another group from China described a large TS that swelled at 5 months after SRS and was surgically removed, but they did not elaborate further. 19 Data from the University of Virginia on Gamma Knife SRS for TSs revealed 3 patients (12%) who experienced worsening facial pain after treatment, with 1 patient undergoing resection revealing lesion extension. 8 However, it is unclear whether these patients were experiencing acute toxicity or failure and likely do not resemble the flare phenomenon.
Both SRS and FSRT have been shown to be effective treatment options for acoustic and nonacoustic schwannomas, including TSs, and the probable equivalency of tumor control puts further emphasis on limiting side effects. Previous data from our institution have documented the use of FSRT for acoustic schwannomas, resulting in not only excellent tumor control, but also superior hearing preservation compared with SRS. 20 Results were similar for large acoustic Schwannomas, with data revealing improved facial and trigeminal nerve tolerance with FSRT. 14, 21 Our institution reviews all patients at a multidisciplinary tumor board where patients are thoroughly discussed. Extrapolating results from the previously mentioned studies, we generally recommend FSRT for patients with functioning cranial nerves. We also recommend FSRT in an effort to exploit the ability of normal tissue cells to repair more efficiently within treatment fractions than tumor cells, potentially manifesting as reduced toxicity. This leaves the finding of the tumor flare phenomenon in the FSRT group unexpected. Both patients had generally larger tumors that were symptomatic at presentation and required surgical resection because of their bulky size. Although our primary goal of surgery is gross total resection of TSs, both underwent subtotal resection because of their degree of invasion. Therefore, the risk-to-benefit ratio still favored treatment because of residual tumor; however, steps may be taken in the future to avoid similar flare of size and symptoms with comparable patients. One reasonable approach is more aggressive tumor debulking or resection, if possible, as well as early initiation of prophylactic oral Decadron (dexamethasone) during radiation treatment to potentially reduce tumor edema. The retrospective nature of this report is a limitation of this study, as is the case with all documented experience in treating TSs with radiotherapy. A randomized trial is necessary to accurately compare SRS and FSRT for TSs.
However, because of the rarity of the lesions, this is unlikely to occur.
Although both patients with the flare phenomenon were treated with FSRT, it is more likely that tumor size, cystic component, and possibly more aggressive biology ultimately contributed to the transient increase in symptoms and size. Both lesions were grade I schwannomas on pathology; however, both had previously failed resection, suggesting aggressive characteristics. Also, it is important to note that MRI is not routinely ordered for symptoms encountered during and directly after radiotherapy for TS; therefore, this may underestimate the number of patients who actually experience this flare phenomenon. However, because of the excellent overall control rate for TSs, it is unlikely that the transient increase in size has significant effect on long-term tumor control. In addition, just as the dose for the treatment of acoustic neuromas was lowered to 46.8 in a dose de-escalation trial with no decrease in tumor control, perhaps a similar trial in TSs is warranted. 20 
CONCLUSION
Tumor control rates for TSs are excellent with both SRS and FSRT with minimal toxicity. However, there appears to be an increased risk of transient enlargement and increased toxicity of large, cystic lesions undergoing treatment. In our experience, no surgical intervention was required, and the patients' symptoms were controlled with steroids and narcotics. This represents the first documented report of a flare phenomenon in a series of patients undergoing both FSRT and SRS for treatment for TSs. Flare risk after FSRT in larger lesions that have undergone previous surgical resection should be discussed with patients before treatment, and prophylactic oral steroid use may be considered.
Disclosure
T his is an excellent article from a group that traditionally has compared results of stereotactic-guided single-dose radiation (SRS) with those of stereotactic-guided fractions of radiation (SRT) for lesions in the brain. They need to be commended for their careful and unbiased analysis of their data. Unfortunately, this is a small sample and reviewed in a retrospective fashion. This just reflects the rarity of trigeminal schwannomas (TSs) and the difficulty of organizing a randomized clinical trial on such a scarce controversial subject. This is more so when the belief of our neurosurgery community leans toward resection, although more and more, single dose and few fractions are being accepted by neurosurgeons as primary treatment of various cranial base lesions. The Thomas Jefferson University's group has, however, managed to use full conventional fractionation schemes to check the advantages of this approach for function preservation compared with SRS. They have consistently reported on the advantage of traditional schemes of radiation therapy associating exquisite stereotactic localization and radiosugery (SRS) comformality for function preservation. They have even demonstrated a trend toward better tumor control with SRT, although tumor control was never statistically in favor of FSRT because of the excellent tumor control obtained with both approaches, as reported here. Our group has reported similar experience when treating benign cranial base tumors. [1] [2] [3] Patients prefer single-dose radiation, mainly now that frameless radiosurgery is available, obviating the uncomfortable application of the stereotactic frame. However, for large lesions, FSRT may be the only approach possible, short of a surgical debulking, followed by SRS.
The novelty of this report is the higher incidence of acute and transient complications in the FSRT group compared with the SRS group. The trend to better tumor control may possibly be attributed to the larger margin added around the tumor, owing to uncertainties of the repeated fixation necessary for a large number of fractions, more than 25 replacements of the localization device. This is now obviated with the use of image-guided techniques with online imaging. Conversely, when a single dose is applied, less margin surrounding the tumor is allowed, seeking the smallest prescription treatment volume (PTV) possible over the gross tumor volume (GTV), avoiding a high dose of radiation to structures to be preserved. The authors elaborated well the importance of the larger volume of the lesions treated by FSRT compared with the ones treated with SRS to explain the higher number of patients experiencing transient adverse effects in the FSRT group. Here the margin of the PTV may also play a role because the structures to be preserved already have the mass effect of the lesion, although tolerating in the long-term the dose prescribed, may have the acute effect of the repeated fractions of radiation. This phenomenon is well described in the radiation oncology literature as the transient acute effects of radiation therapy in the central nervous system. The flair phenomenon appears to reflect the tumor size and swelling with mass effect in surrounding structures, if one analyzes tumor volume vs adverse effects. The tumor causing the most severe side effect, ie, dysarthria, was the one with the largest volume (28.52 mL). This calls attention to the need of decompression in specific situations. The tumors with flair reaction were also the ones for which resection had already failed, suggesting a more aggressive biology and the consequent stronger reaction to radiation.
Over all, this is an excellent study taking into account advantages and disadvantages of 2 different approaches. It candidly singles out the complications observed and the control rate when applying stereotactic radiation to TSs. It gives enough information for physicians to educate patients appropriately and for patients to make informed decision.
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